Sanofi Pasteur Inaugurates High-Tech Vaccine Production Facility
Sanofi Pasteur (Lyon, France), the vaccines division of the Sanofi-Aventis Group, has announced the inauguration of a high-tech vaccine production facility in France to respond to soaring demand worldwide.
The euro100-million facility, located in Val de Reuil, France, incorporates the latest technology to produce vaccines that meet the highest standards of quality. It is a part of euro600-million investments undertaken by Sanofi Pasteur in France between 2005 and 2008.
The highly automated facility can produce vaccines against 20 diseases. It is designed to be ready to switch to pandemic influenza vaccine in the event of a human pandemic influenza, after a pandemic influenza strain is identified by the World Health Organization.
Roche Facilitates Corporate Pandemic Stockpiling of Tamiflu
Roche (Nutley, NJ) has introduced a flexible purchase program that will allow US businesses to maintain access to their own stockpile of Tamiflu for use in a pandemic situation, with limited upfront investment and more adaptability to deal with unknown factors inherent in pandemic planning.
Under the new plan, businesses pay a nominal annual fee to "reserve" their own stockpile of Tamiflu, which Roche will store and rotate to keep "in date." The contract comes up for renewal annually, at which time companies will have the opportunity to re-evaluate their investment decision.
If and when a company decides to take possession of the medicine-for example, if a novel strain of influenza virus begins human-to-human spread-they can purchase their dedicated product from Roche at the prevailing wholesale price. Roche will guarantee delivery within 48 hours in most circumstances.
No comments:
Post a Comment